The Bill & Melinda Gates Foundation, the United States President's Emergency Plan for AIDS Relief (PEPFAR), the U.S. Agency for International Development (USAID), and UNITAID have formed a partnership that will significantly cut the cost of a new rapid diagnostic test for tuberculosis in 145 high-burden and developing countries (HBDC). Funds provided by this partnership will reduce the cost of Xpert MTB/RIF cartridges from $16.86 to $9.98, a price which will not increase until 2022. To date, the high unit cost of Xpert® MTB/RIF cartridges produced by the medical device manufacturer Cepheid has proven a barrier to their introduction and widespread use in low- and middle-income countries. The new agreement will reduce the cost of cartridges used to diagnose TB by more than 40 percent. To make the price reduction effective immediately, the Gates Foundation has agreed to fund an initial payment of $3.5 million to Cepheid. The incremental scaling of the test in high-burden countries could enable the rapid diagnosis of seven hundred thousand cases of TB and save health systems more than $18 million in direct health costs.